Qiagen launches liquid biopsy tests for lung, prostate cancer

Qiagen (NYSE:QGEN) today launched two liquid biopsy panels designed to evaluate circulating tumor cells isolated from a patient’s blood samples.

The company’s lung and prostate cancer diagnostic tests will be introduced at the annual meeting of the American Association for Cancer Research in Chicago, according to Qiagen.

Get the full story at our sister site, Drug Delivery Business News.

The post Qiagen launches liquid biopsy tests for lung, prostate cancer appeared first on MassDevice.

from MassDevice https://ift.tt/2ITlmtT